EA200200847A1 - Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов - Google Patents

Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов

Info

Publication number
EA200200847A1
EA200200847A1 EA200200847A EA200200847A EA200200847A1 EA 200200847 A1 EA200200847 A1 EA 200200847A1 EA 200200847 A EA200200847 A EA 200200847A EA 200200847 A EA200200847 A EA 200200847A EA 200200847 A1 EA200200847 A1 EA 200200847A1
Authority
EA
Eurasian Patent Office
Prior art keywords
piperazine
piperidine
derivatives
prevention
treatment
Prior art date
Application number
EA200200847A
Other languages
English (en)
Inventor
Рональд Томлинсон
Дэвид Лоффер
Майкл Малликан
Original Assignee
Вертекс Фармасьютикалз Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вертекс Фармасьютикалз Инкорпорейтед filed Critical Вертекс Фармасьютикалз Инкорпорейтед
Publication of EA200200847A1 publication Critical patent/EA200200847A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Настоящее изобретение относится к производным пиперазина и пиперидина, которые особенно пригодны для лечения или предупреждения повреждения нейронов, особенно повреждения, связанного с неврологическими заболеваниями. Данные соединения также пригодны для стимуляции роста нервной ткани. Изобретение также представляет композиции, включающие соединения по настоящему изобретению, и способы применения данных композиций для лечения или предотвращения повреждения нейронов или для стимуляции роста нервной ткани.Отчет о международном поиске был опубликован 2002.04.25.
EA200200847A 2000-02-11 2001-02-09 Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов EA200200847A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18194400P 2000-02-11 2000-02-11
US24733000P 2000-11-10 2000-11-10
PCT/US2001/004210 WO2001058891A2 (en) 2000-02-11 2001-02-09 Piperazine and piperidine derivatives for treatment or prevention of neuronal damage

Publications (1)

Publication Number Publication Date
EA200200847A1 true EA200200847A1 (ru) 2003-02-27

Family

ID=26877657

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200847A EA200200847A1 (ru) 2000-02-11 2001-02-09 Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов

Country Status (23)

Country Link
EP (1) EP1257544B1 (ru)
JP (1) JP2003522767A (ru)
KR (1) KR20020073586A (ru)
CN (1) CN1210274C (ru)
AP (1) AP2002002596A0 (ru)
AU (1) AU4146401A (ru)
BR (1) BR0108175A (ru)
CA (1) CA2398822A1 (ru)
CO (1) CO5261503A1 (ru)
CZ (1) CZ20022720A3 (ru)
EA (1) EA200200847A1 (ru)
EE (1) EE200200442A (ru)
HR (1) HRP20020737A2 (ru)
HU (1) HUP0301391A3 (ru)
IL (1) IL150849A0 (ru)
IS (1) IS6477A (ru)
MX (1) MXPA02007790A (ru)
NO (1) NO20023787L (ru)
NZ (1) NZ520638A (ru)
PE (1) PE20011081A1 (ru)
PL (1) PL357177A1 (ru)
SK (1) SK11452002A3 (ru)
WO (1) WO2001058891A2 (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809093B2 (en) * 2000-10-17 2004-10-26 H. Lee Moffitt Cancer & Research Institute, Inc. 2-substituted heterocyclic compounds
EP1383501B1 (en) 2001-02-28 2007-04-04 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
AU2002255597B8 (en) 2001-02-28 2006-10-26 Merck Sharp & Dohme Corp. Acylated piperidine derivatives as melanocortin-4 receptor agonists
DE60232238D1 (de) 2001-02-28 2009-06-18 Merck & Co Inc Acylierte piperidinderivate als melanocortin-4-rezeptoragonisten
CA2453609C (en) 2001-07-18 2010-05-04 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
PE20030703A1 (es) * 2001-09-06 2003-08-21 Schering Corp Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3
US20030191110A1 (en) * 2001-11-01 2003-10-09 Martyn Botfield Modulators of the cholesterol biosynthetic pathway
JP2006505531A (ja) 2002-09-11 2006-02-16 メルク　エンド　カムパニー　インコーポレーテッド メラノコルチン−４受容体作働薬としてのピペラジン尿素誘導体
US20040180880A1 (en) * 2002-10-03 2004-09-16 Lauffer David J. Piperazine and piperidine derivatives
AR043434A1 (es) * 2003-03-03 2005-07-27 Merck & Co Inc Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos
PL1622569T3 (pl) 2003-04-24 2016-06-30 Incyte Holdings Corp Pochodne aza spiro alkanów jako inhibitory metaloproteaz
EP1524265A1 (en) * 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors
CA2574156A1 (en) 2004-07-19 2006-02-23 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
ES2337727T3 (es) * 2005-06-20 2010-04-28 Schering Corporation Derivados de piperidina utiles como antagonistas de histamina h3.
US7408066B2 (en) 2005-06-20 2008-08-05 Schering Corproation Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
GB0514018D0 (en) * 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
EP1988920A1 (en) 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist
KR101181194B1 (ko) 2006-10-18 2012-09-18 화이자 프로덕츠 인코포레이티드 바이아릴 에터 우레아 화합물
JP5514831B2 (ja) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療のための置換二環式アミン
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011137024A1 (en) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
EP2568812B1 (en) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
EP2579873A4 (en) 2010-06-11 2013-11-27 Merck Sharp & Dohme NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
EA030631B1 (ru) * 2013-07-31 2018-09-28 Новартис Аг 1,4-дизамещенные аналоги пиридазинхинолина и способы лечения состояний, связанных с smn-дефицитом
JP6985179B2 (ja) * 2018-02-27 2021-12-22 田辺三菱製薬株式会社 プロリンアミド化合物の製造方法
JP2022534425A (ja) 2019-05-31 2022-07-29 イケナ オンコロジー， インコーポレイテッド Ｔｅａｄ阻害剤およびその使用
SG11202113129UA (en) 2019-05-31 2021-12-30 Ikena Oncology Inc Tead inhibitors and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791501A (fr) * 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
US3862937A (en) * 1972-02-23 1975-01-28 Univ Mississippi 6-Phenethyl-3-piperidinecarboxamides
FR2597100A1 (fr) * 1986-01-21 1987-10-16 Nippon Shinyaku Co Ltd Derives du pyroglutamide
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
US5232923A (en) * 1988-03-18 1993-08-03 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives and pharmaceutical preparations containing same
NZ228329A (en) * 1988-03-18 1991-12-23 Mitsui Toatsu Chemicals Catechol derivatives and pharmaceutical compositions thereof
US5290793A (en) * 1989-09-12 1994-03-01 Mitsui Toatsu Chemicals, Incorporated Dihydrocaffeic acid derivatives and pharmaceutical preparation containing same
FR2705095B1 (fr) 1993-05-12 1995-06-23 Adir Nouveaux indoles substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5614547A (en) 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US5811434A (en) * 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
PA8442401A1 (es) * 1996-12-09 2000-05-24 Guilford Pharm Inc Inhibidores polipropilos de ciclofilina
JPH11106375A (ja) * 1997-08-18 1999-04-20 Pfizer Pharmaceut Inc ブラジキニンアンタゴニストとしての光学的に活性な１，４−ジヒドロピリジン化合物

Also Published As

Publication number Publication date
CO5261503A1 (es) 2003-03-31
NZ520638A (en) 2004-05-28
HUP0301391A2 (hu) 2003-08-28
MXPA02007790A (es) 2002-10-17
CN1210274C (zh) 2005-07-13
IL150849A0 (en) 2003-02-12
EE200200442A (et) 2003-12-15
KR20020073586A (ko) 2002-09-27
AP2002002596A0 (en) 2002-09-30
WO2001058891A2 (en) 2001-08-16
PL357177A1 (en) 2004-07-26
EP1257544A2 (en) 2002-11-20
CN1404477A (zh) 2003-03-19
AU4146401A (en) 2001-08-20
JP2003522767A (ja) 2003-07-29
HUP0301391A3 (en) 2010-03-29
IS6477A (is) 2002-07-19
NO20023787L (no) 2002-10-11
SK11452002A3 (sk) 2003-03-04
CZ20022720A3 (cs) 2002-11-13
BR0108175A (pt) 2003-01-28
EP1257544B1 (en) 2012-07-25
HRP20020737A2 (en) 2005-10-31
PE20011081A1 (es) 2001-10-22
CA2398822A1 (en) 2001-08-16
WO2001058891A3 (en) 2002-04-25
NO20023787D0 (no) 2002-08-09

Similar Documents

Publication Publication Date Title
EA200200847A1 (ru) Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
NO20052153L (no) Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.
DE60027431D1 (de) Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
ATE386544T1 (de) Photodynamische therapie zur behandlung von haarausfall
EP1474158A4 (en) PREVENTING AND TREATING OXIDATIVE STRESS RELATED DISORDERS USING GLUTATHIONE AND PHASE II DETOXIFICATION ENZYMES
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
PL348715A1 (en) Carboxylic acids and carboxylic acid isosteres of n−heterocyclic compounds
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
DE60124085D1 (de) Pde-v hemmer zur behandlung von morbus parkinson
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
EA200001247A1 (ru) N-связанные сульфонамиды n-гетероциклических карбоновых кислот или изостеры карбоновых кислот
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
DE60014136D1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE59907195D1 (de) Verfahren zur behandlung von erkrankungen oder störungen des innenohrs
ATE252387T1 (de) Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen
DE69822626T8 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
ATE302011T1 (de) PONAZURIL ZUR BEHANDLUNG VON DURCH COCCIDIA NEUROLOGISCHEN UND ßABORTIGENICß VERURSACHTEN ERKRANKUNGEN
DE60318081D1 (de) Verwendung von brimonidine zur behandlung von dementia und morbus parkinson
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen